DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Thursday. They currently have a $76.00 price objective on the medical device company’s stock, down from their prior price objective of $85.00. Wedbush’s price objective would indicate a potential upside of 55.34% from the stock’s current price.

DXCM has been the subject of a number of other reports. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Robert W. Baird reissued a “hold” rating and set a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. Barclays PLC assumed coverage on DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. Canaccord Genuity reissued a “buy” rating and set a $90.00 price target on shares of DexCom in a report on Wednesday, June 7th. Finally, BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and an average price target of $75.14.

DexCom (NASDAQ DXCM) traded up 7.669% during mid-day trading on Thursday, hitting $48.925. The stock had a trading volume of 9,357,971 shares. The stock’s 50 day moving average price is $72.62 and its 200 day moving average price is $73.86. DexCom has a one year low of $45.61 and a one year high of $94.24. The firm’s market capitalization is $4.23 billion.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. During the same period last year, the firm posted ($0.24) earnings per share. The business’s revenue was up 24.3% on a year-over-year basis. Analysts forecast that DexCom will post ($0.79) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Wedbush Reiterates “Outperform” Rating for DexCom, Inc. (DXCM)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/30/wedbush-reiterates-outperform-rating-for-dexcom-inc-dxcm.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $69.47, for a total transaction of $100,731.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The disclosure for this sale can be found here. Insiders have sold a total of 32,223 shares of company stock worth $2,285,138 in the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Independent Portfolio Consultants Inc. grew its position in DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after acquiring an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. grew its position in DexCom by 1.9% during the 2nd quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after acquiring an additional 69 shares during the last quarter. Public Employees Retirement Association of Colorado grew its position in DexCom by 0.4% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after acquiring an additional 83 shares during the last quarter. King Luther Capital Management Corp grew its position in DexCom by 0.7% during the 1st quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock worth $1,026,000 after acquiring an additional 90 shares during the last quarter. Finally, World Asset Management Inc grew its position in DexCom by 4.1% during the 2nd quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock worth $285,000 after acquiring an additional 155 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.